Researchers at Umeå University, Sweeden, and international collaborators have developed a promising fully human antibody against agressive prostate cancer in preclinical testing. So, yes this is not available yet, but it shows promise against slowing the cancer when it is ready to jump from the prostate to the rest of the body. Most men who have prostate cancer can watch and wait - it is one of the slowest growing cancers and has a 98% success rate of cure for 10 years or more; when caught before spreading outside the prostate. That is the dangerous step, once it spreads to the lymph nodes or bones, things become much more difficult. This antibody (published in 'Signal Transduction and Targeted Therapy') was able to slow tumor growth and block metastasis (process where cancer spreads to other parts of the body), in preclinical studies of agressive prostate cancer. Maréne Landström, Professor of Pathology at the Department of Medical Biosciences, Umeå University, who led the study; say they have been able to identify the mechanisms that drive cancer cell growth, invasiveness and metastatic spread. "Agressive Prostate Cancer needs more options for treatment." Most prostate cancers are slow growing and men will die of old age or something else before it becomes a problem. But, in those rare case where the cancer is aggressive, new treatments are needed, and this antibody shows promise. Landström and colleagues led the development of a fully human antibody (made entirely from human proteins). This makes the antibody more suitable for people. In preclinical trials, the antibody stopped both tumor growth and metastic spread of an agressive form of prostate cancer. The treatment attacks the cancer through a biological route, that differs from existing treatments, it is a new mechanism. The researchers believe this will lead to reduced side effects. The antibody behaved as intended in the models tested, which is important in moving forward towards clinical use.